Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease

被引:5
|
作者
Shi, Yichao [1 ,2 ]
Li, Jianfeng [2 ]
Cai, Shuntian [2 ]
Zhao, Hong [3 ]
Zhao, Huijun [2 ]
Sun, Gang [2 ]
Yang, Yunsheng [2 ,4 ]
机构
[1] Peking Univ, Aerosp Ctr Hosp, Dept Gastroenterol, Aerosp Sch Clin Med, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
关键词
gastroesophageal reflux disease; proton pump inhibitor; fecal mycobiota; Candida; gastric mucosal mycobiota; LONG-TERM USE; CANDIDA-ALBICANS; COMMENSAL FUNGI; THERAPY; MICROBIOME; RISK; INFLAMMATION; PROPHYLAXIS; MEDICATION; ESOPHAGUS;
D O I
10.3389/fcimb.2023.1205348
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gut mycobiota inhabits human gastrointestinal lumen and plays a role in human health and disease. We investigated the influence of proton pump inhibitors (PPIs) on gastric mucosal and fecal mycobiota in patients with gastroesophageal reflux diseases (GERD) by using Internal Transcribed Spacer 1 sequencing. A total of 65 participants were included, consisting of the healthy control (HC) group, GERD patients who did not use PPIs (nt-GERD), and GERD patients who used PPIs, which were further divided into short-term (s-PPI) and long-term PPI user (l-PPI) groups based on the duration of PPI use. The alpha diversity and beta diversity of gastric mucosal mycobiota in GERD patients with PPI use were significantly different from HCs, but there were no differences between s-PPI and l-PPI groups. LEfSe analysis identified Candida at the genus level as a biomarker for the s-PPI group when compared to the nt-GERD group. Meanwhile, Candida, Nothojafnea, Rhizodermea, Ambispora, and Saccharicola were more abundant in the l-PPI group than in the nt-GERD group. Furthermore, colonization of Candida in gastric mucosa was significantly increased after PPI treatment. However, there was no significant difference in Candida colonization between patients with endoscopic esophageal mucosal breaks and those without. There were significant differences in the fecal mycobiota composition between HCs and GERD patients regardless whether or not they used PPI. As compared to nt-GERD patient samples, there was a high abundance of Alternaria, Aspergillus, Mycenella, Exserohilum, and Clitopilus in the s-PPI group. In addition, there was a significantly higher abundance of Alternaria, Aspergillus, Podospora, Phallus, and Monographella in the l-PPI group than nt-GERD patients. In conclusion, our study indicates that dysbiosis of mycobiota was presented in GERD patients in both gastric mucosal and fecal mycobiota. PPI treatment may increase the colonization of Candida in the gastric mucosa in GERD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] COST ANALYSIS OF PROTON PUMP INHIBITORS IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN UKRAINE
    Iakovlieva, L.
    Gerasymova, O.
    Mishchenko, O.
    Bezditko, N.
    Kyrychenko, O.
    Kuznetsov, I
    VALUE IN HEALTH, 2015, 18 (07) : A623 - A624
  • [32] FACTORS AFFECTING EFFICACY OF GASTROESOPHAGEAL REFLUX DISEASE TREATMENT WITH PROTON PUMP INHIBITORS
    Lazebnik, L. B.
    Bordin, D. S.
    Masharova, A. A.
    Firsova, L. D.
    Silvestrova, S. Yu.
    TERAPEVTICHESKII ARKHIV, 2012, 84 (02) : 16 - 21
  • [33] Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors
    Hershcovici, Tiberiu
    Fass, Ronnie
    CURRENT OPINION IN GASTROENTEROLOGY, 2010, 26 (04) : 367 - 378
  • [34] Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
    Jaroslaw Kierkus
    Grzegorz Oracz
    Bartosz Korczowski
    Edyta Szymanska
    Anna Wiernicka
    Marek Woynarowski
    Drug Safety, 2014, 37 : 309 - 316
  • [35] Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease
    Tjon, James A.
    Pe, Michael
    Soscia, Joanna
    Mahant, Sanjay
    PHARMACOTHERAPY, 2013, 33 (09): : 956 - 971
  • [36] Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors
    Tonini, M.
    Vigneri, S.
    Neri, M.
    Cuomo, R.
    Savarino, V.
    Pace, F.
    DIGESTION, 2007, 76 (3-4) : 171 - 178
  • [37] Comparison of Daily Average Consumption Between Different Proton Pump Inhibitors in Patients with Gastroesophageal Reflux Disease
    Baser, Onur
    Mody, Reema
    Xie, Lin
    Baser, Erdem
    Morlock, Robert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S414 - S415
  • [38] Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
    Ivan Kristo
    Katrin Schwameis
    Svenja Maschke
    Alexander Kainz
    Erwin Rieder
    Matthias Paireder
    Gerd Jomrich
    Sebastian F. Schoppmann
    Scientific Reports, 8
  • [39] Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors
    Hongo, Michio
    Miwa, Hiroto
    Kusano, Motoyasu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (05) : 913 - 918
  • [40] Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
    Kristo, Ivan
    Schwameis, Katrin
    Maschke, Svenja
    Kainz, Alexander
    Rieder, Erwin
    Paireder, Matthias
    Jomrich, Gerd
    Schoppmann, Sebastian F.
    SCIENTIFIC REPORTS, 2018, 8